Maria Elisa Mancuso: During Day 2 of the Annual EHC Conference We Discussed Very Rare Bleeding Disorders!
Maria Elisa Mancuso, Senior Hematology Consultant at Humanitas Research Hospital, shared on LinkedIn:
”During Day 2 of the Annual EHC Conference in Vienna we discussed very rare bleeding disorders as fibrinogen defects (thanks to Alessandro Casini) and the “newly recognized” group of Bleeding Disorders of Unknown Cause – BDUC (thanks to Johanna Gebhart).
Congratulations to Dominik Cepic for is wonderful overview and passionate advocacy for hemophilia B with inhibitors as “rare among rares”.
The SLAM session shed lights to many important issues as orthopedic evaluation and care of arthropathy, treatment of PUPs, pain and ITI.
During the session dedicated to gene therapy real world experience (Wolfgang Miesbach), struggles in procurement and reimbursement (Gaetan Duport) and new non-AAV mediated gene therapies (Paul Batty) were discussed.
Finally the day was beautifully close by the energy of the youth debates.”
More from EHC 2025 featured in Hemostasis Today.
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia